GUTS
FRACTYL HEALTH, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.38
−10.97%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.44
From 52W high−71.72%
Volume1.13M
Market cap$18.31M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.44
From 52W high
−71.72%
Volume
1.13M
Market cap
$18.31M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
40.8
MomentumView details →
1D Return
−10.97%
YTD Return
−33.64%
SummaryUpdated Jun 1, 2026
Fractyl Health, Inc. (NASDAQ:GUTS) is a metabolic therapeutics company founded in 2010 and based in Lexington, Massachusetts. The company was formerly known as Fractyl Laboratories Inc. before changing its name in June 2021. Fractyl went public on NASDAQ in 2024, focusing on developing innovative therapies for type 2 diabetes and obesity. The company operates two main therapeutic platforms: the Revita procedural therapy system and the Rejuva gene therapy platform, both targeting the growing global epidemic of metabolic diseases.
Similar companies
Latest newsMore news →
FRACTYL HEALTH, INC. reported that its ongoing REMAIN-1 pivotal study met the six-month co-primary endpoint, with 80% retention of GLP-1-induced weight loss for Revita versus 67% for sham.4d agoKuehn Law, PLLC is investigating whether certain officers and directors of Fractyl Health, Inc. breached their fiduciary duties to shareholders.26d ago